Identification and targeting of selective vulnerability rendered by tamoxifen resistance

Identification and targeting of selective vulnerability rendered by tamoxifen resistance

Abstract Background The estrogen receptor (ER)-positive breast cancer represents over 80% of all breast cancer cases. Even though adjuvant hormone therapy with tamoxifen (TMX) is saving lives of patients with ER-positive breast cancer, the acquired resistance to TMX anti-estrogen therapy is the main...

Full description

Bibliographic Details
Main Authors: Madhurendra Singh, Xiaolei Zhou, Xinsong Chen, Gema Sanz Santos, Sylvain Peuget, Qing Cheng, Ali Rihani, Elias S. J. Arnér, Johan Hartman, Galina Selivanova
Format: Article
Language:English
Published: BMC 2020-07-01
Series:Breast Cancer Research
Subjects:
Tamoxifen resistance
SULT1A1
RITA
Aminoflavone
Oncrasin-1
TrxR1
Online Access:http://link.springer.com/article/10.1186/s13058-020-01315-5

Internet

http://link.springer.com/article/10.1186/s13058-020-01315-5

Similar Items